

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.;  
Nandabalan, Krishnan; and Stephens, J. Claiborne.

Application No.: To be assigned  
Filed: March 16, 2001

Group No.: To be assigned  
Examiner: To be assigned

For: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG  
RESPONSE

**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

**PRELIMINARY AMENDMENT TO CLAIMS**  
**(37 C.F.R. 1.121 and M.P.E.P. 714.09)**

This application is a continuation of pending PCT application PCT/US00/10125. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

**IN THE CLAIMS**

Please cancel claims 9-12 and 21-24 without prejudice or disclaimer

**REMARKS**

Upon entry of this amendment, claims 1-8, 13-20, and 25-29 are pending. This amendment cancels claims that are being pursued in a separate continuation application of PCT/US00/10125 filed concurrently herewith. Should any questions arise, or if Applicants or Applicants' Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.;  
Nandabalan, Krishnan; and Stephens, J. Claiborne.

Application No.: To be assigned  
Filed: March 16, 2001

Group No.: To be assigned  
Examiner: To be assigned

For: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG  
RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT TO CLAIMS**  
**(37 C.F.R. 1.121 and M.P.E.P. 714.09)**

This application is a continuation of pending PCT application PCT/US00/10125. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

**IN THE CLAIMS**

Please cancel claims 9-12 and 21-24 without prejudice or disclaimer

**REMARKS**

Upon entry of this amendment, claims 1-8, 13-20, and 25-29 are pending. This amendment cancels claims that are being pursued in a separate continuation application of PCT/US00/10125 filed concurrently herewith. Should any questions arise, or if Applicants or Applicants' Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.